JP2014518216A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518216A5
JP2014518216A5 JP2014516067A JP2014516067A JP2014518216A5 JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5 JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014516067 A JP2014516067 A JP 2014516067A JP 2014518216 A5 JP2014518216 A5 JP 2014518216A5
Authority
JP
Japan
Prior art keywords
inclusive
insulin
concentration
composition
hyaluronidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518216A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042816 external-priority patent/WO2012174478A2/en
Publication of JP2014518216A publication Critical patent/JP2014518216A/ja
Publication of JP2014518216A5 publication Critical patent/JP2014518216A5/ja
Pending legal-status Critical Current

Links

JP2014516067A 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤 Pending JP2014518216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161520962P 2011-06-17 2011-06-17
US61/520,962 2011-06-17
PCT/US2012/042816 WO2012174478A2 (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016200761A Division JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Division JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Publications (2)

Publication Number Publication Date
JP2014518216A JP2014518216A (ja) 2014-07-28
JP2014518216A5 true JP2014518216A5 (https=) 2015-07-23

Family

ID=46513830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014516067A Pending JP2014518216A (ja) 2011-06-17 2012-06-15 ヒアルロナン分解酵素の安定な製剤
JP2016200761A Active JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016200761A Active JP6224802B2 (ja) 2011-06-17 2016-10-12 ヒアルロナン分解酵素の安定な製剤
JP2017111643A Pending JP2017197556A (ja) 2011-06-17 2017-06-06 ヒアルロナン分解酵素の安定な製剤

Country Status (13)

Country Link
EP (1) EP2720712B1 (https=)
JP (3) JP2014518216A (https=)
KR (2) KR101874401B1 (https=)
CN (2) CN105797140B (https=)
AU (2) AU2012271359B2 (https=)
BR (1) BR112013032396A2 (https=)
CA (1) CA2839511C (https=)
EA (2) EA201400031A1 (https=)
ES (1) ES2566549T3 (https=)
IL (1) IL229749A0 (https=)
MX (1) MX340172B (https=)
NZ (2) NZ618331A (https=)
WO (1) WO2012174478A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
ES2804719T3 (es) * 2013-02-04 2021-02-09 Sanofi Sa Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素(insulin glulisine)的穩定調配物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
JP6562902B2 (ja) * 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
CN104095871A (zh) * 2014-07-10 2014-10-15 青岛蔚蓝生物股份有限公司 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液
AU2015289619C1 (en) 2014-07-16 2021-01-07 New York University Use of hyaluronidase for treatment of muscle stiffness
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
CN114835793A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
JP6798030B2 (ja) 2016-09-06 2020-12-09 シンファー ティアン−リー ファーマシューティカル カンパニー リミテッド(ハンツォウ)Sinphar Tian−Li Pharmaceutical Co., Ltd. (Hangzhou) 皮膚ケアおよび/または創傷治癒促進における松塊抽出物およびその有効成分の使用
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
CN108070532A (zh) * 2016-11-16 2018-05-25 福建力多利生物科技有限公司 一种生产葡萄糖氧化酶的方法
WO2019050749A1 (en) * 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
CN107918020B (zh) * 2017-11-15 2019-01-01 浙江夸克生物科技有限公司 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
CN120699939A (zh) * 2020-01-23 2025-09-26 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
US12221638B2 (en) 2020-08-07 2025-02-11 Alteogen Inc. Method for producing recombinant hyaluronidase
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル-マイヤーズ スクイブ カンパニー Pd1/pd-l1抗体の皮下投与
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
JP2024501721A (ja) * 2020-12-30 2024-01-15 上海宝済薬業股▲ふん▼有限公司 組換えヒトヒアルロニダーゼ製剤およびその用途
JP2024541973A (ja) * 2021-10-29 2024-11-13 アルテオジェン・インコーポレイテッド ヒトヒアルロニダーゼph20及び薬物を含む医薬組成物
CN115820766B (zh) * 2021-12-28 2024-11-12 华熙生物科技股份有限公司 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
CN120475959A (zh) * 2022-12-23 2025-08-12 韩美药品株式会社 包含免疫活性白细胞介素2类似物缀合物的制剂
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN117243852A (zh) * 2023-11-01 2023-12-19 华熙生物科技股份有限公司 一种皮肤外用组合物及其用途
CN119074669B (zh) * 2024-06-21 2025-04-18 邢珺月 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
EP0250119A3 (en) * 1986-06-20 1990-04-18 Vasocor Atherosclerotic anti-idiotype antibody immunoassay and reagents
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6563022B2 (en) * 1999-07-05 2003-05-13 Toyo Boseki Kabushiki Kaisha Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
DK1282599T3 (da) * 2000-05-19 2006-07-31 Alcon Inc Disulfidderivater, der er egnede til behandling af allergiske sygdomme
US6902548B1 (en) * 2001-03-19 2005-06-07 Ed Schuler Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
US20030125234A1 (en) * 2001-12-11 2003-07-03 Middaugh Charles Russell Alteration of protein stability
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2521940C (en) * 2003-04-23 2010-01-26 Latrobe University Insect chymotrypsin and inhibitors thereof
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
WO2005095625A1 (en) * 2004-03-31 2005-10-13 Hexima Ltd Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
WO2005118799A1 (en) * 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
JP2009512709A (ja) * 2005-10-20 2009-03-26 エムディーアールエヌエー,インコーポレイテッド 速効型インスリンの経鼻投与
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
CN102596175A (zh) * 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
CA2839512C (en) * 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
WO2013102144A2 (en) * 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2014518216A5 (https=)
US20240238382A1 (en) URI Agonist/Vasodilator
US11020459B2 (en) Factor VIII formulations
KR101978527B1 (ko) 펩티드 약물의 비경구 주입을 위한 안정한 제형
AU2007322334B2 (en) Method of drug delivery for bone anabolic protein
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
JP2018138578A5 (https=)
CN1120019C (zh) 含NaCl的胰岛素制品
US20180036411A1 (en) Stable Formulation of Insulin Glulisine
US8338374B2 (en) Stable growth hormone liquid formulation
KR20160105979A (ko) 인슐린-아연 복합체의 제조 방법
US20210283259A1 (en) Protein formulations
KR20200037235A (ko) 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료
IL277721B2 (en) Medical infusion pump system for the delivery of an insulin compound
CA3011902C (en) Liquid insulin formulations and methods relating thereto
KR101932247B1 (ko) 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법